Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

Intel has stood by Tan, and in a statement told The Wall Street Journal that its board and management were aligned on strategy. Before Trump jumped into the fray, Tan was already at odds with some of ...

Kennedy’s $500M cut to mRNA funding puts startups at risk and imperils one of life sciences’ few leasing bright spots.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

With a 5.98% market share, India is the fourth-largest pharmaceutical supplier to the U.S., behind Ireland, Switzerland, and ...

Californians are trading in their sun-filled coastal lives for this undiscovered paradise - as locals reveal the incredible ...

Let's see why these funds could be worth holding onto for the long term. The post 5 high-quality ASX ETFs to buy and hold for ...